Targeting tumor hypoxia in nasopharyngeal carcinoma

@article{Hong2013TargetingTH,
  title={Targeting tumor hypoxia in nasopharyngeal carcinoma},
  author={Bo Hong and Vivian Wai Yan Lui and Masumi Hashiguchi and Edwin Pun Hui and Anthony Tak-cheung Chan},
  journal={Head \& Neck},
  year={2013},
  volume={35}
}
Nasopharyngeal carcinoma (NPC) is an endemic head and neck cancer in Southeast Asia. Although concurrent chemoradiotherapy generally results in good clinical response for early diseases, posttreatment relapse and distant metastasis are major causes for NPC deaths. There is an urgent need for more effective therapies for advanced NPC. Recent studies have demonstrated tumor hypoxia can be a therapeutic target in NPC. 
View on Wiley
sbccp.org.br
42 Citations
Highly Influential Citations
2
Background Citations
22
Results Citations
1

42 Citations

Citation Type

Citation Type

Alterations in genetic pathways following radiotherapy for head and neck cancer
TLDR
It is hypothesized there would be alterations in gene‐expression and pathway activity in HNC samples obtained in recurrent HNC that were previously treated with RT, when compared to RT‐naïve disease.
Hypoxia in Head and Neck Squamous Cell Carcinoma
TLDR
The mechanisms involved in the resistance of radiotherapy and chemotherapy in hypoxic condition are discussed and the molecular mechanisms employed by the HNSCC cells to adapt the hypoxia condition and their tumorigenic role in head and neck are exploited.
Investigational drugs for nasopharyngeal carcinoma
TLDR
This review focused on the latest clinical development of the most promising classes of investigational agents in the treatment of advanced NPC, which include inhibitors of tumor angiogenesis, kinase signaling pathways and immunotherapy.
The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment
TLDR
The stromal landscape of NPC is depicted in detail based on recent advances, and various microenvironment-based approaches for precision therapy are proposed.
Advances and challenges in intensity-modulated radiotherapy for nasopharyngeal carcinoma.
TLDR
Traditional intensity-modulated radiation therapy, helical tomotherapy, and new challenges in the management of nasopharyngeal carcinoma are reviewed.
Patient-Derived Nasopharyngeal Cancer Organoids for Disease Modeling and Radiation Dose Optimization
TLDR
This study is the first direct experimental evidence to predict optimal RT boost dose required to cause sufficient damage to recurrent hypoxic NPC tumor cells, which can be further used to develop dose-painting algorithms in clinical practice.
Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China
TLDR
The RTOG IMRT protocols are feasible for patients with NPC from the endemic regions of China, and T and N category were significant prognostic factors for OS, FFS, RRFS and DMFS.
Local control and failure patterns after intensity modulated radiotherapy with reduced target volume delineation after induction chemotherapy for patients with T4 nasopharyngeal carcinoma
Long-term Patterns of Regional Failure for Nasopharyngeal Carcinoma following Intensity-Modulated Radiation Therapy
TLDR
The regional failure of NPC after treatment with IMRT is uncommon but is significantly higher in N2-3 patients than in N0-1 patients, and N stage was the only independent prognostic predictor of RFFS.
Distant Metastasis Risk Definition by Tumor Biomarkers Integrated Nomogram Approach for Locally Advanced Nasopharyngeal Carcinoma
TLDR
A nomogram-based Cox proportional regression model is designed to refine the metastasis risk of each NPC individuals through integrating a panel of tumor biomarkers, supporting by this nomogram algorithm the individual metastasisrisk might be refined personally and potentially guiding the treatment decisions and target therapy against the related signaling pathways for patients with locally advanced NPC.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 161 REFERENCES
State-of-the-art management of nasopharyngeal carcinoma: current and future directions
TLDR
Phase III clinical trials support the addition of chemotherapy to radiotherapy for the initial treatment of patients with newly diagnosed Nasopharyngeal carcinoma, a distinct type of head and neck cancer.
Nasopharyngeal carcinomas: an update.
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma
This single‐center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinum‐based chemotherapy.
Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions
TLDR
The purposes of this review are to provide the latest results and future directions of clinical and translational research for this disease, and to illustrate how some of these new therapies have improved the treatment outcome for patients with NPC.
Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments
  • Q. Tao, A. Chan
  • Biology, Medicine
    Expert Reviews in Molecular Medicine
  • 2007
TLDR
New biomarkers for NPC, including EBV DNA copy number or methylation of multiple tumour suppressor genes, which can be detected in serum and nasopharyngeal brushings, have been developed for the molecular diagnosis of this tumour.
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
  • C. Elser, L. Siu, +10 authors E. Chen
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Sorafenib was well tolerated and had modest anticancer activity comparable to monotherapy with other targeted agents in this group of patients, and further development in combination with radiation or other agents may be warranted.
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck.
Hypoxia in head and neck cancer: How much, how important?
TLDR
The biology and importance of hypoxia in head and neck cancer is reviewed to show the presence and extent of tumor Hypoxia as a negative prognostic indicator.
Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation
TLDR
Encouraging results from this proof-of-concept study implicate the therapeutic potential of hypoxia-targeting approaches for the treatment of NPC.
Elevated plasma big ET‐1 is associated with distant failure in patients with advanced‐stage nasopharyngeal carcinoma
Endothelin‐1 (ET‐1) is a potent vasoactive peptide and a hypoxia‐inducible angiogenic growth factor associated with the development and spread of solid tumors. The clinical significance of plasma big…
...
1
2
3
4
5
...